The Johns Hopkins Center for Health Security has published the first working definition of Global Catastrophic Biological Risks (GCBRs) to place new focus on a special category of biological risks that have received too limited research and effort given their potential for harm to humanity.
Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity in reach for all people.
GHTC policy officer, Courtney Carson, was featured in CSIS' "Take as Directed" podcast hosted by Steve Morrison, covering the new report Return on innovation: Why global health R&D is a smart investment for the United States and its key findings.
GHTC's report Return on innovation: Why global health R&D is a smart investment for the United States, highlighting global health R&D's economic returns, was covered in IP Watch.
.png)
One of the most overlooked benefits of US-funded global health research is the training provided to scientists to do the work in their own communities.
Jamie Rosen is the media & communications manager for Aeras, a GHTC member. Aeras and the TuBerculosis Vaccine Initiative (TBVI) recently hosted a booth at the Union World Conference on Lung Health to hear from conference attendees about the need for a new TB vaccine. This blog post reflects what Aeras heard and experienced at the conference.
